Published in J Clin Oncol on March 21, 2005
Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg (2009) 1.51
Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res (2007) 1.31
ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun (2013) 1.27
Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol (2012) 1.23
Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer (2006) 1.14
NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia (2011) 1.13
Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol (2006) 1.11
Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc (2008) 1.10
Gastric cancer: surgery in 2011. Langenbecks Arch Surg (2011) 1.05
Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. J Transl Med (2014) 1.04
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol (2013) 1.04
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer (2011) 1.01
Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther (2011) 0.99
Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer (2013) 0.95
Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest (2013) 0.94
Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol (2011) 0.94
The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. Gastrointest Cancer Res (2008) 0.93
Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol (2016) 0.91
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer (2011) 0.90
Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer (2011) 0.90
Multimodal treatment of esophageal cancer. Langenbecks Arch Surg (2012) 0.88
Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol (2012) 0.88
Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus (2008) 0.87
Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res (2008) 0.86
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs (2006) 0.86
Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist. World J Surg Oncol (2006) 0.86
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer (2009) 0.85
Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol (2005) 0.85
Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer (2011) 0.84
Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist (2010) 0.83
A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol (2015) 0.82
Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer. Ann Thorac Surg (2015) 0.82
Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg (2014) 0.81
Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review. Cancer Biol Med (2014) 0.81
Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol (2015) 0.81
Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. Radiat Oncol (2015) 0.81
Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg (2014) 0.81
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol (2007) 0.80
18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer (2015) 0.79
Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Oncol (2014) 0.79
A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer (2016) 0.78
Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. Front Oncol (2016) 0.78
Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. Radiat Oncol J (2015) 0.77
Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy. Medicine (Baltimore) (2015) 0.77
NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression. Oncotarget (2015) 0.77
Nm23H1 mediates tumor invasion in esophageal squamous cell carcinoma by regulation of CLDN1 through the AKT signaling. Oncogenesis (2016) 0.77
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer. Int J Clin Exp Pathol (2014) 0.77
Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status. World J Gastroenterol (2015) 0.77
Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. Sci Rep (2015) 0.77
Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol (2013) 0.76
Time course of serum C-reactive protein levels during induction chemoradiotherapy and its correlation with treatment response and survival in patients with advanced esophageal squamous cell carcinoma. Mol Clin Oncol (2013) 0.76
Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology (2015) 0.76
Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol (2009) 0.76
Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol (2007) 0.76
Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today (2015) 0.75
Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis. Mol Clin Oncol (2017) 0.75
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol (2016) 0.75
Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience. Curr Oncol (2014) 0.75
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer (2016) 0.75
The Effect of Neoadjuvant Therapy on Early Complications of Esophageal Cancer Surgery. Iran J Otorhinolaryngol (2015) 0.75
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. Oncotarget (2016) 0.75
Preoperative therapy for potentially resectable localized gastric cancer. Gastrointest Cancer Res (2009) 0.75
FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy. BMC Med Imaging (2017) 0.75
Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer (2017) 0.75
Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer. J Gastrointest Oncol (2014) 0.75
Survival benefit of surgery to patients with esophageal squamous cell carcinoma. Sci Rep (2017) 0.75
Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett (2016) 0.75
Factors associated with false-negative endoscopic biopsy results after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Medicine (Baltimore) (2015) 0.75
Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol (2012) 0.75
Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysis. Medicine (Baltimore) (2017) 0.75
Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett (2017) 0.75
Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res (2017) 0.75
Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary. J Thorac Dis (2017) 0.75
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
The B73 maize genome: complexity, diversity, and dynamics. Science (2009) 18.73
The accessible chromatin landscape of the human genome. Nature (2012) 16.86
Systematic localization of common disease-associated variation in regulatory DNA. Science (2012) 14.47
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
An expansive human regulatory lexicon encoded in transcription factor footprints. Nature (2012) 7.27
The genome of woodland strawberry (Fragaria vesca). Nat Genet (2010) 5.86
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol (2003) 4.44
Global regulation of erythroid gene expression by transcription factor GATA-1. Blood (2004) 4.22
LTR_FINDER: an efficient tool for the prediction of full-length LTR retrotransposons. Nucleic Acids Res (2007) 3.89
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol (2003) 3.27
Reference genome sequence of the model plant Setaria. Nat Biotechnol (2012) 3.21
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
De novo genome sequencing and comparative genomics of date palm (Phoenix dactylifera). Nat Biotechnol (2011) 2.94
A temporal chromatin signature in human embryonic stem cells identifies regulators of cardiac development. Cell (2012) 2.81
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
The genome of the pear (Pyrus bretschneideri Rehd.). Genome Res (2012) 2.55
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol (2014) 2.38
Diaqua-bis(5-carb-oxy-2-propyl-1H-imidazole-4-carboxyl-ato-κN,O)manganese(II) N,N-dimethyl-formamide disolvate. Acta Crystallogr Sect E Struct Rep Online (2009) 2.35
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg (2009) 2.31
Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer (2014) 2.24
Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest (2007) 2.19
Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19
Antagonistic HLH/bHLH transcription factors mediate brassinosteroid regulation of cell elongation and plant development in rice and Arabidopsis. Plant Cell (2009) 2.17
Ultrasound-guided peripheral intravenous access in the emergency department using a modified Seldinger technique. J Emerg Med (2009) 2.08
Defibrillation delivered during the upstroke phase of manual chest compression improves shock success. Crit Care Med (2010) 2.04
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest (2002) 2.02
Optimum lymphadenectomy for esophageal cancer. Ann Surg (2010) 2.01
catena-Poly[[diaqua-(1,10-phenanthroline-κN,N')nickel(II)]-μ-1H-benzimidazole-5,6-dicarboxyl-ato-κN:O]. Acta Crystallogr Sect E Struct Rep Online (2009) 1.99
Techniques for teaching electrocardiogram interpretation: self-directed learning is less effective than a workshop or lecture. Med Educ (2011) 1.95
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis (2004) 1.92
Penta-aqua-(1H-benzimidazole-5,6-di-carboxyl-ato-κN)cobalt(II) penta-hydrate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.92
Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl (2009) 1.86
Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci U S A (2007) 1.81
Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res (2007) 1.80
Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci Transl Med (2012) 1.80
Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One (2011) 1.78
Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med (2011) 1.76
New best1 mutations in autosomal recessive bestrophinopathy. Retina (2015) 1.75
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72
Widespread site-dependent buffering of human regulatory polymorphism. PLoS Genet (2012) 1.72
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res (2009) 1.71
Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int J Cancer (2010) 1.67
Relation of low vitamin D to nonvalvular persistent atrial fibrillation in Chinese patients. Ann Noninvasive Electrocardiol (2013) 1.66
Compound prioritization methods increase rates of chemical probe discovery in model organisms. Chem Biol (2011) 1.64
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol (2005) 1.63
Genetic evidence linking SAP, the X-linked lymphoproliferative gene product, to Src-related kinase FynT in T(H)2 cytokine regulation. Immunity (2004) 1.63
Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol (2013) 1.63
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62
Protein kinase C and A sites on troponin I regulate myofilament Ca2+ sensitivity and ATPase activity in the mouse myocardium. J Physiol (2003) 1.62
Obesity and restless legs syndrome in men and women. Neurology (2009) 1.61
Interstrand DNA cross-links induced by alpha,beta-unsaturated aldehydes derived from lipid peroxidation and environmental sources. Acc Chem Res (2008) 1.60
Management of acquired bronchobiliary fistula: A systematic literature review of 68 cases published in 30 years. World J Gastroenterol (2011) 1.59
Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer (2006) 1.59
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain (2010) 1.59
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol (2013) 1.57
Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest (2015) 1.54
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Axon guidance by diffusible chemoattractants: a gradient of netrin protein in the developing spinal cord. J Neurosci (2006) 1.51
Postresuscitation myocardial diastolic dysfunction following prolonged ventricular fibrillation and cardiopulmonary resuscitation. Crit Care Med (2008) 1.51
Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Nucl Med Mol Imaging (2014) 1.51
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A (2013) 1.49
Risk factors for early postoperative complications after pneumonectomy for benign lung disease. Ann Thorac Surg (2013) 1.49
Predicting malignancy in mediastinal lymph nodes by endobronchial ultrasound: a new ultrasound scoring system. Respirology (2012) 1.47
A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J Proteome Res (2009) 1.46
Diaqua-bis(5-carb-oxy-2-propyl-1H-imidazole-4-carboxyl-ato-κN,O)nickel(II) N,N-dimethyl-formamide disolvate. Acta Crystallogr Sect E Struct Rep Online (2010) 1.45
Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation (2010) 1.45
Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med (2003) 1.45
Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns (2002) 1.44
Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum Immunol (2010) 1.43
Individual effect of components of defibrillation waveform on the contractile function and intracellular calcium dynamics of cardiomyocytes. Crit Care Med (2009) 1.43
G protein activation without a GEF in the plant kingdom. PLoS Genet (2012) 1.43
Stereoselectivity of satropane, a novel tropane analog, on iris muscarinic receptor activation and intraocular hypotension. Acta Pharmacol Sin (2008) 1.42
Matrix metalloprotease 9 promotes liver recovery from ischemia and reperfusion injury. J Surg Res (2012) 1.41
Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med (2007) 1.40
High-performance III-V MOSFET with nano-stacked high-k gate dielectric and 3D fin-shaped structure. Nanoscale Res Lett (2012) 1.40
DNase I-hypersensitive exons colocalize with promoters and distal regulatory elements. Nat Genet (2013) 1.40
Penta-aqua-(1H-benzimidazole-5,6-dicarboxyl-ato-κN)nickel(II) penta-hydrate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.39
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res (2005) 1.39
A survey of women regarding factors affecting colorectal cancer screening compliance. Prev Med (2004) 1.38
High-speed digital-image correlation method. Opt Lett (2009) 1.38
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas (2008) 1.38
Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer (2005) 1.37
Gastric cancer. J Natl Compr Canc Netw (2010) 1.35
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther (2007) 1.35
Aligned ZnO/CdTe core-shell nanocable arrays on indium tin oxide: synthesis and photoelectrochemical properties. ACS Nano (2010) 1.35
Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus. Clin Chem (2003) 1.34
Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2012) 1.34
Sun protection and skin surveillance practices among relatives of patients with malignant melanoma: prevalence and predictors. Prev Med (2004) 1.33
Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest (2008) 1.33
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther (2005) 1.32
Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis (2013) 1.31
The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.30
Influencing factors of symptomatic anastomotic leakage after anterior resection of the rectum for cancer. World J Surg (2009) 1.30